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The HTLV-1 virus is a known agent involved in the development of HAM/TSP. Past studies have typically observed patients with
autonomic dysfunction consisting of detrusor overactivity and detrusor-sphincter dyssynergia, with the occasional observation
of underactive detrusor or detrusor arreﬂexia. However, studies have not yet evaluated the progression of neurogenic bladder
over time. In this paper, we describe a HAM/TSP patient with the initial development of overactive detrusor, and subsequent
development of detrusor arreﬂexia. Given a paucity of studies characterizing the eﬀects of HTLV-1 on the autonomic nervous
system, particularly aspects controlling continence, this patient’s clinical course may represent one type of end point for patients
with HAM/TSP and neurogenic bladder. Further cohort or case-series studies, with particular emphasis on the progression of
neurogenicbladder, are needed to evaluatethe signiﬁcanceofthis described caseinrelationto typical diseaseprogressionpatterns.
1.Introduction
T h eH u m a nT - L y m p h o t r o p i cV i r u sT y p e1( H T L V - 1 )i sa n
RNAvirusandaknownagentinvolvedinthedevelopmentof
HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [1]. Speculation exists as to the current preva-
lence of HTLV-1 infection [2], but the most widely quoted
estimate in the literature continues to be 10–20 million
people worldwide [3]. Of those infected with HTLV-1, it is
estimated that about four percent develop HAM/TSP [4].
The infection is endemic in tropical and subtropical areas,
with higher prevalence in Central and South America, the
south of Japan, and Africa [5].
HAM/TSPisachronicmyelopathy witha clinicalpresen-
tationofspasticparaparesis, includingpyramidal eﬀectssuch
as hyperreﬂexia and Babinskisign. Autonomicdysfunction is
alsoobserved,as wellas occasionalmildsensation abnormal-
ities and/or pain [6]. Overactive bladder (OAB) is the most
commonautonomicpresentationinpatientswithHAM/TSP
butcanalsooccurasanisolated formin patientswith HTLV-
1 infection and without paraparesis [5, 7]. Urodynamic
studies in individuals with HAM/TSP alongside symptoms
of frequency and diﬃculty voiding typically reveal detrusor
overactivity(DO)anddetrusor-sphincter dyssynergia (DSD)
compatible with a myelopathy picture [8]. Studies have also
found individuals with underactive or detrusor arreﬂexia
(DA) and resulting overﬂow incontinence, though this is less
commonly observed [9, 10].
In this paper, our objective is to describe a HAM/TSP
patient with initial OAB due to DO, and subsequent
development of DA and overﬂow incontinence.
2.Case Presentation
The patient is a 70-year-old female with HTLV-I infection
and a ﬁve-year diagnosis of HAM/TSP. Two years ago, the
patient developed OAB initially characterized by urgency
with incontinence and nocturia. However, over the past six
months,thepatientceasedtohaveurgencyandbeganrequir-
ing regular self-catheterization for voiding. The patient does
not have a history of diabetes, hypertension, syphilis, or HIV.2 Case Reports in Medicine
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Figure 1: Urodynamic study performed on patient (2008) showing detrusor hyperreﬂexia prior to voiding. PV: vesicular pressure, PR:
abdominalpressure, PV-PR: detrusor pressure, Vol: volume in bladder.
On a routine outpatient neurologic exam, the patient
was alert and oriented. Proximal asymmetric paraparesis
grade 4 (Medical Research Council [11]) was noted on
ﬂexion of the leg at the right hip, and grade 4+ was noted
on ﬂexion of the leg at the left hip. Grade 2 spasticity
(Ashworth Scale [12]) was observed on passive movement
of the legs. Global hyperreﬂexia, grade 3 (Campbell Score
[13]), and bilateral Babinski sign were also noted. Sensation
was normal, and there was no alteration in coordination nor
in equilibrium. The patient was classiﬁed according to the
Kurtzke Expanded Disability Status Scale (EDSS) [14]a n d
the Osame Disability Motor Scale (ODMS) [15], with scores
of 4 and 5, respectively.
Urodynamic studies were conducted on this patient in
both 2008 and 2010. In these studies, a 12Fr trilumen
catheter was transurethrally inserted into the bladder to
measure vesicular pressure, while abdominal pressure was
measured by intrarectal balloon catheter. Detrusor pres-
sure was obtained by subtracting abdominal pressure from
bladder pressure. In 2008, the studies revealed OAB with
DSD and OD (Figure 1). However, studies in 2010 revealed
DA and an inability to void during pressure-ﬂow studies
(Figure 2), consistent with the patient’s loss of urgency and
continued incontinence.
A urinary sonogram performed in 2010 notes a
postvoid residual volume of 357cm3 and bilateral, grade
II hydronephrosis with communicative hypoechoic areas
observed in both kidneys (Figure 3); this is consistent with
the eﬀects of overﬂow incontinence due to noncontractile
bladder. At this time, the right kidney measured 8.92cm in
greatest diameter, while the left kidney measured 9.47cm.
The patient’s most recent routine urine analysis and cultures
in 2010 were unremarkable, with creatinine and blood
urea nitrogen (BUN) within normal range and indicating
preserved renal function.
Initially, upon development of OD, the patient was
treated with anticholinergics. However, prevention of
residual urine now requires regular catheterization. The
patient was educated to perform self-catheterization and
tolerates the procedure well.Case Reports in Medicine 3
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Figure 2: Urodynamic study performed on patient(2010)displayingdetrusor arreﬂexia. Pves:vesicular pressure, Pabd: abdominalpressure,
Pdet: detrusor pressure, Vur: urine volume, Vinf: infusion volume.
3.Discussion
OAB and OD, with or without DSD, are a common feature
in patients with HTLV-1, especially those with HAM/TSP.
In a urodynamic evaluation of HTLV-1-infected patients
with and without HAM/TSP, de Castro et al. [8] described
OD in 37% of HTLV-1 patients without HAM/TSP and in
46.9% of patients with a diagnosis of HAM/TSP. Alongside
OD, DSD was described in 11% and 34% of the patients,
respectively. However, DA was not described in any patients
in this study. Likewise, similar studies by Lima et al. [16],
Imamura et al. [10], and Yamashita and Kumazawa [17]
observed OD ranging from 60–96% among patients with
HAM/TSP. Lima and Yamashita also noted DSD in 35% and
65% of HAM/TSP patients, respectively.
Few studies have described patients with DA. In
Yamashita’s study of 26 HAM/TSP patients, only one patient
was observed to have DA on urodynamic evaluation. In a
similar fashion, in a study of 25HAM/TSP patients, Ima-
mura found DA in four (16%) patients and hydronephrosis
in two (8%). And, though both OD and DA have been
observed in past studies of patients with HAM/TSP, these
studies were not conducted with the purpose of providing
information regarding the temporal progression of auto-
nomic dysfunction in HAM/TSP.
This paper describes a patient with known HAM/TSP
who ﬁrst developed OD, with progression to DA after two
years.Asnocohortstudieshaveyetdescribedtheprogression
of neurogenic bladder in HAM/TSP patients over time, it is
unknown whether this patient’s manifestations correspond
to the natural history of bladder dysfunction in HAM/TSP
or to an alternative and less-common form of progression.
A progression from OD to underactive detrusor, with the
eventual development of DA, may correspond with an initial
lesion in the spinal cord nuclei and tracts and a subsequent
neuronal secondary degeneration of bladder innervation.
Interestingly, Komine et al. [9] described two patients
similar to our case with underactive detrusor, three and six
years after the diagnosis of HAM/TSP. Yet, in a previous
study [18]b yt h i sg r o u p ,1 6p a t i e n t sa l lw i t hO Da n d
most with DSD had an average duration of HAM/TSP of
12.7 years. Such information suggests the possibility of a
reverse progression of autonomic dysfunction from that
suggested above, with OD occurring as a later manifestation,
or possibly that the development of DA is an altered course
of neurologic pathology in some patients and occurs for4 Case Reports in Medicine
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Figure 3: Urinary sonogramperformed on patient (2010) revealing grade II hydronephrosis consistent with noncontractile bladder.
yet unknown reasons. Cohorts with repeat urodynamic
studiesareneededtoevaluatetheprogression ofneurological
symptoms in more patients and to determine whether a
temporal progression from OD to DA is an alternative
outcome in HAM/TSP patients.
From a clinical perspective, as there is a large range in
urinary symptoms among patients with HTLV-1 infection
(particularly those with HAM/TSP), it is important to
regularly re-evaluatepatientsforchangesinbladderfunction
and provide speciﬁc treatment options.
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